Research Associate Professor Scientific Director, Marian S. Ware Alzheimer and Benaroya Parkinson’s Disease Drug Discovery Programs Dr. Burnden’s proposal is close behind Puglieli’s in terms of proximity to animal model testing, after Brunden does some toxicology. Brudens proposal focuses on a family of aminothienopyridizine (ATPZs) compounds that emerged from 290,000 compound screens for drugs to block tangle formation in AD. He has identified several ATPZs that are worthy of bringing forward in animal studies.
read moreThe Leissering lab studies substances (called proteases) that destroy amyloid beta-protein which is the chief component of the plaques that create Alzheimer’s disease. Dr. Leissring previous work has shown that the severity of Alzheimer’s Disease is strongly dependent on how active these protease substances are. However, all of the various amyloid destroying substances (proteases) are not known. Dr. Leissring is using CART funds to investigate most of these substances and determine which ones are capable of destroying...
read morePaul Murphy, University of Kentucky ($250,000 2yr. Grant) Alzheimer’s disease is sometimes called “the diabetes” of the brain, because, like diabetes, it is common and shares some common features including accumulation of proteinaceous deposits called amyloid. Moreover, until recently, it wasn’t apparent that diabetes itself is a risk factor for AD, and insulin, a key hormone regulating the body’s ability to respond to glucose (“sugar”) levels in the blood and centrally involved in the pathogenesis of...
read moreFor the first time in 2008, the CART Fund was able to make two grants in one year. From 56 outstanding applicants, our Scientific Review Committee chaired by Dr. John Trojanowski of the University of Pennsylvania, assisted by Dr. Allan Levey of Emory University and Dr. Karl Herrup of Rutgers University, recommended that our grants be made to Dr. Sanjay Pimplikar of the Cleveland Clinic ($250,000.00) and Dr. David Sweatt of UAB ($200,000.00). Dr. Pimplikar’s research will explore the possibility that an emyloid percusor protein, called...
read more